AMO Development, LLC, contends a high-energy ablating ultraviolet laser can’t correct internal eye problems because it would first destroy corneal tissue because “laser pulses are highly absorbed in whatever tissue they first encounter.” The U.S. Patent Trial and Appeal Board agreed in IPR2021-00856. Alcon Inc., Alcon Vision, LLC, Alcon Laboratories, Inc., and Alcon Research, LLC,…
Alcon & AMO Development Asked Federal Circuit to Re-Review U.S. Patent No. 8,500,724 Prior to Settlement Pact
More from LegalMore posts in Legal »
- Green Creative & Industrial Lighting Deny SemiLED’s UV Lighting Technology Patent Infringement Claims & Assert Nine Affirmative Defenses
- Pictiva Displays & Samsung Electronics Provide Judge Gilstrap with Chart Outlining Patent Language Disputes
- Judge Jordan’s Technical Advisor Bills $35,000 for His Assistance in UV Lighting Patent Technology Litigation
- Ninth Circuit Transfers Finelite’s Appeal Involving Samsung & Seoul Viosys to Federal Circuit
- Green Creative & Industrial Lighting Turn to Duane Morris to Defend SemiLED’s UV Lighting Technology Patent Infringement Claims